Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
A. Rizzotto, S. Tollis, N. T. Pham, Y. Zheng, M. A. Abad, J. Wildenhain, A. A. Jeyaprakash, M. Auer, M. D. Tyers, E. C. Schirmer
The paper shows that DHRS7 loss increases nuclear size in prostate cancer cells and that estradiol propionate reduces nuclear size in DHRS7-lacking cells, suggesting DHRS7 as a biomarker for estrogen therapy effectiveness.
bioRxiv · Sep 18, 2023 · PreprintCancer Biology